A Paradigm Shift in Glioblastoma Treatment and Research: A Multi-mechanistic, Multi-agent Approach to Target Glioblastoma Multiforme

Document Type : Hypothesis



The majority of patients with glioblastoma multiforme (GBM) suffer dismal outcomes. Adopting a broader, multi-mechanistic, multi-agent approach targeting GBM using readily available and fairly benign agents in combination with standard therapy may improve outcomes. Such agents include fluoxetine, fenofibrate, cimetidine, citrulline, valacyclovir, 1,3 1-6 beta glucan, and tadalafil, among others. In the context of in vitro and animal studies, these agents appear to target GBM cells and modify the tumor microenvironment. The current approach to GBM treatment focuses on limited molecular attributes of the condition. The following article highlights the relevance of the aforementioned agents in GBM treatment and proposes a multi-mechanistic, multi-agent paradigm shift, addressing a broader range of molecular attributes in the quest to improve patient outcomes.


  1. Liu KH, Yang ST, Lin JW, Lee YH, Wang JY, Hu CJ, et al. Fluoxetine, an antidepressant, suppresses glioblastoma by evoking AMPAR-mediated calcium-dependent apoptosis. Oncotarget. 2015; 6(7):5088-101. doi: 10.18632/oncotarget.3243
  2. Song T, Li H, Tian Z, Xu C, Liu J, Guo Y. Disruption of NF-kB signaling by fluoxetine attentuates MGMT expression in glioma cells. Journal of OncoTargets and Therapy. 2015; 8:2199-2208. doi: 10.2147/ott.s85948
  3. Han D, Wei W, Chen X, Zhang Y, Wang Y, Zhang J, et al. NF-kB/RelA-PKM2 mediates inhibition of glycolysis by fenofibrate in gliobastoma cells. Oncotarget. 2015; 6(28):26119-26128. doi: 10.18632/oncotarget.4444
  4. Wilk A, Wyczechowska D, Zapata A, Dean M, Mullinax J, Marrero L, et al. Molecular mecanisms of fenobrate-induced metabolic catastrophe and glioblastoma cell death. Molecular and Cellular Biology. 2014; 35(1):182-198. doi: 10.1128/mcb.00562-14
  5. Grabacka MM, Wilk A, Antonczyk A, Banks P, Walczyk-Tytko E, Dean M, et al. Fenofibrate induces ketone body production in melanoma and glioblastoma cells. Front Endocrinol (Lausanne). 2016; 7:5. doi: 10.3389/fendo.2016.00005
  6. Pantsiarka P, Bouche G, Meheus L, Sukhatme V, Sukhatme VP. Repurposing drugs in oncology (ReDO)-cimetidine as an anti-cancer agent. Ecancermedicalscience. 2014; 8(2):485. doi: 10.3332/ecancer.2016.680
  7. Zheng Y, Xu M, Li X, Jia J, Fan K, Lai G. Cimetidine suppresses lung tumor growth in mice through proapoptosis of myeloid-derived suppressor cells. Molecular Immunology. 2013; 54(1):7483. doi: 10.1016/j.molimm.2012.10.035
  8. Lefranc F, James S, Camby I, Gaussin JF, Darro F, Brotchi J, et al. Combined cimetidine and temozolomide, compared with temozolomide alone: significant increases in survival in nude mice bearing U373 human glioblastoma multiforme orthotopic xenografts. Journal of Neurosurgery. 2005; 102(4):706-14. doi: 10.3171/jns.2005.102.4.0706
  9. Li B, Cao F, Zhu Q, Li B, Gan M, Wang D. Perioperative cimetidine administration improves systematic immune response and tumor infiltrating lymphocytes in patients with colorectal cancer. Hepatogastroenterology. 2013; 60(122):244-7. doi: 10.5754/hge12573
  10. Srivastava MK, Sinha P, Clements VK, Rodriguez P, Ostrand-Rosenberg S. Myeloid-derived suppressor cells inhibit T cell activation by depleting cystine and cysteine. Cancer Res. 2009; 70(1):68-77. doi: 10.1158/0008-5472.can-09-2587
  11. Sevko A, Umansky V Myeloid-derived suppressor cells interact with tumors in terms of myelopoiesis, tumorigenesis and immunosuppression: thick as thieves. Journal of Cancer. 2013; 4(1):3-11. doi: 10.7150/jca.5047
  12. Bansal V, Rodriguez P, Wu G, Eichler DC, Zabaleta J, Taheri F. Citrulline can preserve proliferation and prevent the loss of CD3 zeta chain under conditions of low arginine. Journal of Parenteral and Enteral Nutrition. 2004; 28(6):423-430. doi: 10.1177/0148607104028006423
  13. Wainwright W, Chang AL, Dey M, Balyasnikova, IV, Kwon Kim C, Tobias A, et al. Durable therapeutic efficacy utilizing combinational blockade against IDO, CTLA-4 and PD-L1 in mice with brain tumors. Clinical Cancer Research. 2014; 20(20):5290-5301. doi: 1078-0432.ccr-14-0514
  14. Weed DT, Vella JL, Reis IM, De la fuente AC, Gomez C, Sargi Z, et al. Tadalafil reduces myeloid-deived supressor cells and regulatory T cells and promotes tumor immunity in patients with head ad neck squamous cell carcinoma. Clinical Cancer Research. 2014; 21(1):39-48. doi: 10.1158/1078-0432.ccr-14-1711
  15. Serafini P, Meckel K, Kelso M, Noonan K, Califano J, Koch W, et al. Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function. Journal of Experimental Medicine. 2006; 203(12):2691-702. doi: 10.1084/jem.20061104
  16. De Haas N, De Koning C, Spilgies L, De Vries IJM, Hato SV Improving cancer immunotherapy by targeting the STATe of MDSCs. Oncoimmunology. 2016; 5(7):1196312. doi: 10.1080/2162402x.2016.1196312
  17. Soderlund J, Erhardt S, Kast RE. Acyclovir inhibition of IDO to decrease Tregs as a glioblastoma treatment adjunct. Journal of Neuroinflammation. 2010; 7:44. doi: 10.1186/1742-2094-7-44
  18. Wainwright DA, Balyasnikova IV, Chang AL, Ahmed AU, Moon K-S, Auffinger B, et al. IDO expression in brain tumors increases the recruitment of regulatory T cells and negatively impacts survival. Clinical Cancer Research. 2012; 18(22):6110-6121.doi: 10.1158/1078-0432.ccr-12-2130
  19. Ong S-Y, Truong H-T-T, Diong CP, Linn Y-C, Yew-Leng Ho A, Goh Y-T, et al. Use of valacyclovir for the treatment of cytomegalovirus antigenemia after hematopoietic stem cell transplantation. BMC Hematology. 2015; 15:8. doi: 10.1186/s12878-015-0028-2
  20. Tian J, Ma J, Ma K, Guo H, Baidoo SE, Zhang Y, et al. Beta-glucan enhances antitumor immune responses by regulating differentiation and function of monocytic myeloid-derived suppressor cells. European Journal of Immunology. 2013; 43(5):1220-1230. doi: 10.1002/eji.201242841
  21. Hong F, Hansen RD, Yan J, Allendorf DJ, Baran JT, Ostroff GR, et al. Beta-glucan functions as an adjuvant for monoclonal antibody immunotherapy by recruiting tumoricidal granulocytes as killer cells. Cancer Research. 2003; 63(24):9023-9031. PMID: 14695221
  22. Hong F, Yan J, Baran JT, Allendorf DJ, Hansen RD, Ostroff GR, et al. Mechanism by which orally administered beta-1,3-glucans enhance the tumoricidal activity of antitumor monoconal antibodies in murine tumor models. Journal of Immunology. 2004; 173(2):797-806. doi: PMID: 15240666
  23. Soderlund J, Erhardt S, Kast RE. Acyclovir inhibition of IDO to decrease Tregs as a glioblastoma treatment adjunct. Journal of Neuroinflammation. 2010; 7(1):44. doi: 10.1186/1742-2094-7-44
  24. Black KL, Yin D, Ong JM, Hu J, Konda BM, Wang X, et al. PDE5 inhibitors enhance tumor permeability and efficacy of chemotherapy in a rat brain tumor model. Brain Research. 2008; 1230:290-302. doi: 10.1016/j.brainres.2008.06.122
  25. Triscott J, Lee C, Hu K, Fotovati A, Berns R, Pambid M, et al. Disulfiram, a drug used widely to control alcoholism, suppresses self-renewal of glioblastoma and overrides resistance to temozolomide. Oncotarget. 2012; 3(10):1112-1123. doi: 10.18632/oncotarget.604